MicroRNA-34a in cardiovascular disease: a glimpse into the future

Alieva A.M.; Reznik E.V.; Teplova N.V.; Melikulov A.A.; Akhmedova M.F.; Kotikova I.A.; Nikitin I.G.

doi:https://doi.org/10.17116/Cardiobulletin20231801114

Close metadata

Abstract:

Epigenetic processes involved in regulation of cardiovascular functions including regulatory role of microribonucleic acids (miRNAs) are being actively studied all over the world. Significant changes of miRNAs expression in many diseases have made it possible to consider them as perspective biomarkers. In this review, we discussed the main studies demonstrating potential role of miRNA-34a in cardiovascular diseases. Experimental and clinical studies have demonstrated significance of miRNA-34a in cardiovascular diseases. Overexpression of miRNA-34a has been shown to suppress autophagy and promote cardiovascular apoptosis, inflammation, fibrosis, remodeling, aging and cardiac dysfunction. Inhibition of miRNA-34a enhances autophagy, reduces apoptosis and provides antioxidant and antifibrotic effects on cardiovascular system. This review presents regulatory role of miRNA-34a in cardiovascular diseases and provides evidence of benefits of miRNA-34a as a potential therapeutic target. Further additional preclinical and clinical trials are needed to identify potential benefits and side effects of miRNA-34a inhibitors in cardiovascular diseases.

Keywords:

cardiovascular diseases

biological markers

miRNA-34a

atherosclerosis

coronary artery disease

heart failure

Authors:

Alieva A.M.

Pirogov Russian National Research Medical University

Reznik E.V.

Pirogov Russian National Research Medical University

Teplova N.V.

Pirogov Russian National Research Medical University

SPIN RSCI: 9056-1948
Scopus AuthorID: 6603037947
ORCID: 0000-0003-4259-0945

Melikulov A.A.

AKFA Medline Clinic

Akhmedova M.F.

AKFA Medline Clinic

Kotikova I.A.

Pirogov Russian National Research Medical University

Nikitin I.G.

Pirogov Russian National Research Medical University

Received:

07.11.2022

Accepted:

29.11.2022

Close metadata

References:

Alieva AM, Teplova NV, Kislyakov VA, Voronkova KV, Shnakhova LM, Valiev RK, Rakhaev AM, Elmurzaeva DA, Malkarova DS, Nikitin IG. Biomarkers in cardiology: microrna and heart failure. Terapija. 2022;1:60-70. (In Russ.). https://doi.org/10.18565/therapy.2022.1.60-70
Khan AA, Gupta V, Mahapatra NR. Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics. Drug Discovery Today. 2022;27(8):2170-2180. https://doi.org/10.1016/j.drudis.2022.05.003
Romakina VV, Zhirov IV, Nasonova SN, Zaseeva AV, Kochetov AG, Liang OV, Tereshchenko SN. MicroRNAs as biomarkers of cardiovascular diseases. Kardiologija. 2018;58(1):66-71. (In Russ.). https://doi.org/10.18087/cardio.2018.1.10083
Chulkova SV, Ryabchikov DA, Dudina IA, Kazakov AM, Egorova AV, Titov KS, Khagazheeva MN, Gladilina IA, Galaeva ZM, Lepkova NV, Tupitsyn NN. The prospects for the use of microRNA as diagnostic and prognostic melanoma biomarkers. Rossijskiy bioterapevticheskiy zhurnal. 2019;18:51-57. (In Russ.). https://doi.org/10.17650/1726-9784-2019-18-4-51-56
Qiao E, Huang Z, Wang W. Exploring potential genes and pathways related to calcific aortic valve disease. Gene. 2022;808:145987. https://doi.org/10.1016/j.gene.2021.145987
Kalayinia S, Arjmand F, Maleki M, Malakootian M, Singh CP. MicroRNAs: roles in cardiovascular development and disease. Cardiovascular Pathology. 2021;50:107296. https://doi.org/10.1016/j.carpath.2020.107296
Hua CC, Liu XM, Liang LR, Wang LF, Zhong JC. Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases. Frontiers in Cardiovascular Medicine. 2022;8:784044. https://doi.org/10.3389/fcvm.2021.784044
Cartas-Espinel I, Telechea-Fernandez M, Manterola Delgado C, Avila Barrera A, Saavedra Cuevas N, Riffo-Campos AL. Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review. ESC Heart Failure. 2022;9(3):1651-1665. https://doi.org/10.1002/ehf2.13735
Raucci A, Macrì F, Castiglione S, Badi I, Vinci MC, Zuccolo E. MicroRNA-34a: the bad guy in age-related vascular diseases. Cellular and Molecular Life Sciences. 2021;78(23):7355-7378. https://doi.org/10.1007/s00018-021-03979-4
Dong F, Dong S, Liang Y, Wang K, Qin Y, Zhao X. MiR-34a promotes myocardial infarction in rats by inhibiting the activity of SIRT1. European Review for Medical and Pharmacological Sciences. 2019;23(16):7059-7065. https://doi.org/10.26355/eurrev_201908_18750
Iekushi K, Seeger F, Assmus B, Zeiher AM, Dimmeler S. Regulation of cardiac microRNAs by bone marrow mononuclear cell therapy in myocardial infarction. Circulation. 2012;125(14):1765-1773. https://doi.org/10.1161/CIRCULATIONAHA.111.079699
Baker JR, Vuppusetty C, Colley T, Papaioannou AI, Fenwick P, Donnelly L, Ito K, Barnes PJ. Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. Scientific Reports. 2016;6:35871. https://doi.org/10.1038/srep35871
He M, Gao L, Zhang S, Tao L, Wang J, Yang J, Zhu M. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer. 2014;17(3):431-441. https://doi.org/10.1007/s10120-013-0313-3
Raddatz MA, Vander Roest MJ, Merryman WD. Notch1 suppression by microRNA-34a: a new mechanism of calcific aortic valve disease. Cardiovascular Research. 2020;116(5):871-873. https://doi.org/10.1093/cvr/cvz280
Wu KH, Xiao QR, Yang Y, Xu JL, Zhang F, Liu CM, Zhang ZM, Lu YQ, Huang NP. MicroRNA-34a modulates the Notch signaling pathway in mice with congenital heart disease and its role in heart development. Journal of Molecular and Cellular Cardiology. 2018;114:300-308. https://doi.org/10.1016/j.yjmcc.2017.11.015
Yu N, Wu JL, Xiao J, Fan L, Chen SH, Li W. HIF-1α regulates angiogenesis via Notch1/STAT3/ETBR pathway in trophoblastic cells. Cell Cycle. 2019;18(24):3502-3512. https://doi.org/10.1080/15384101.2019.1689481
Pan J, Zhou L, Lin C, Xue W, Chen P, Lin J. MicroRNA-34a Promotes Ischemia-Induced Cardiomyocytes Apoptosis through Targeting Notch1. Evidence-Based Complementary and Alternative Medicine. 2022;2022:1388415. https://doi.org/10.1155/2022/1388415
Sakai S, Maruyama H, Kimura T, Tajiri K, Honda J, Homma S, Aonuma K, Miyauchi T. Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells. Life Sciences. 2016;159:116-120. https://doi.org/10.1016/j.lfs.2016.03.044
Huang Y, Qi Y, Du JQ, Zhang DF. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opinion on Therapeutic Targets. 2014;18(12):1355-1365. https://doi.org/10.1517/14728222.2014.961424
Dorn G. miR-34a and the cardiomyopathy of senescence: SALT PNUTS, SALT PNUTS! Cell Metabolism. 2013;17(5):629-630. https://doi.org/10.1016/j.cmet.2013.04.004
Zhang H, Zhao Z, Pang X, Yang J, Yu H, Zhang Y, Zhou H, Zhao J. MiR-34a/sirtuin-1/foxo3a is involved in genistein protecting against ox-LDL-induced oxidative damage in HUVECs. Toxicology Letters. 2017;277:115-122. https://doi.org/10.1016/j.toxlet.2017.07.216
Natarajan S, Stringham B, Mohr A, Wehrkamp C, Lu S, Phillippi M, Harrison-Findik D, Mott J. FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis. Journal of Lipid Research. 2017;58(5):866-875. https://doi.org/10.1194/jlr.M071357
Shao H, Yang L, Wang L, Tang B, Wang J, Li Q. MicroRNA-34a protects myocardial cells against ischemia-reperfusion injury through inhibiting autophagy via regulating TNFα expression. Biochemistry and Cell Biology. 2018;96(3):349-354. https://doi.org/10.1139/bcb-2016-0158
Ni T, Lin N, Lu W, Sun Z, Lin H, Chi J, Guo H. Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy. Cardiovascular Drugs and Therapy. 2020;34(3):291-301. https://doi.org/10.1007/s10557-020-06968-0
Bian W, Tian F, Jiang L, Sun Y, Wu S, Gao B, Kang Z, Zhuo Z, Zhang X. Influence of miR-34a on myocardial apoptosis in rats with acute myocardial infarction through the ERK1/2 pathway. European Review for Medical and Pharmacological Sciences. 2019;23(7):3034-3041. https://doi.org/10.26355/eurrev_201904_17585
Zhang C, Zhang Y, Zhu H, Hu J, Xie Z. MiR-34a/miR-93 target c-Ski to modulate the proliferaton of rat cardiac fibroblasts and extracellular matrix deposition in vivo and in vitro. Cellular Signalling. 2018;46:145-153. https://doi.org/10.1016/j.cellsig.2018.03.005
Bernardo B, Gao X, Winbanks C, Boey E, Tham Y, Kiriazis H, Gregorevic P, Obad S, Kauppinen S, Du X, Lin R, McMullen J. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proceedings of the National Academy of Sciences. 2012;109(43):17615-17620. https://doi.org/10.1073/pnas.1206432109
Mahjoob G, Ahmadi Y, Fatima Rajani H, Khanbabaei N, Abolhasani S. Circulating microRNAs as predictive biomarkers of coronary artery diseases in type 2 diabetes patients. Journal of Clinical Laboratory Analysis. 2022;36(5):e24380. https://doi.org/10.1002/jcla.24380
Xu Y, Xu Y, Zhu Y, Sun H, Juguilon C, Li F, Fan D, Yin L, Zhang Y. Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis. Molecular Therapy. 2020;28(1):202-216. https://doi.org/10.1016/j.ymthe.2019.09.008
Su G, Sun G, Liu H, Shu L, Liang Z. Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels. 2018;33(10):1185-1194. https://doi.org/10.1007/s00380-018-1169-6
Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochemical and Biophysical Research Communications. 2010;398(4):735-740. https://doi.org/10.1016/j.bbrc.2010.07.012
Li X, Lu Z, Zhou F, Jin W, Yang Y, Chen S, Xie Z, Zhao Y. Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro. Vascular Pharmacology. 2020;131:106763. https://doi.org/10.1016/j.vph.2020.106763
Han H, Qu G, Han C, Wang Y, Sun T, Li F, Wang J, Luo S. MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32-patient cohort. Experimental and Molecular Medicine. 2015;47(2):e138. https://doi.org/10.1038/emm.2014.81
Gatsiou A, Georgiopoulos G, Vlachogiannis N, Pfisterer L, Fischer A, Sachse M, Laina A, Bonini F, Delialis D, Tual-Chalot S, Zormpas E, Achangwa R, Jiang L, Kontogiannis C, Patras R, Hermeking H, Zeiher AM, Stamatelopoulos K, Dimmeler S. Additive contribution of microRNA-34a/b/c to human arterial ageing and atherosclerosis. Atherosclerosis. 2021;327:49-58. https://doi.org/10.1016/j.atherosclerosis.2021.05.005
Li H, Chen M, Feng Q, Lin Zhu, Bai Z, Wang B, Guo Z, Hou A, Li H. MicroRNA-34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules. Journal of Clinical Laboratory Analysis. 2022;36(1):e24138. https://doi.org/10.1002/jcla.24138
Li J, Dai J, Han B, Wu G, Wang C. MiR-34a regulates cell apoptosis after myocardial infarction in rats through the Wnt/β-catenin signaling pathway. European Reviews for Medical and Pharmacological Sciences. 2019;23(6):2555-2562. https://doi.org/10.26355/eurrev_201903_17404
Lakhani H, Khanal T, Gabi A, Yousef G, Alam MB, Sharma D, Aljoudi H, Puri N, Thompson E, Shapiro JI, Sodhi K. Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population. PLoS One. 2018;13(10):e0205329. https://doi.org/10.1371/journal.pone.0205329
Zhou R, Wang L, Zhao G, Chen D, Song X, Momtazi-Borojeni AA, Yuan H. Circulating exosomal microRNAs as emerging non-invasive clinical biomarkers in heart failure: Mega bio-roles of a nano bio-particle. IUBMB Life. 2020;72(12):2546-2562. https://doi.org/10.1002/iub.2396
Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, Kawahara Y, Komuro I. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circulation Research. 2013;113(3):322-326. https://doi.org/10.1161/CIRCRESAHA.113.301209
Hu J, Gao C, Wei C, Xue Y, Shao C, Hao Y, Gou LT, Zhou Y, Zhang J, Ren S, Chen J, Wang Y, Fu XD. RBFox2-miR-34a-Jph2 axis contributes to cardiac decompensation during heart failure. Proceedings of the National Academy of Sciences. 2019;116(13):6172-6180. https://doi.org/10.1073/pnas.1822176116
Lv P, Zhou M, He J, Meng W, Ma X, Dong S, Meng X, Zhao X, Wang X, He F. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. International Journal of Molecular Sciences. 2014;15(4):5774-5788. https://doi.org/10.3390/ijms15045774
Fu B, Lang J, Zhang D, Sun L, Chen W, Liu W, Liu K, Ma C, Jiang S, Li R, Tian H. Suppression of miR-34a Expression in the Myocardium Protects Against Ischemia-Reperfusion Injury Through SIRT1 Protective Pathway. Stem Cells and Development. 2017;26(17):1270-1282. https://doi.org/10.1089/scd.2017.0062
Li Q, Ge Z, Xiang Y, Tian D, Tang Y, Zhang YC. Upregulation of microRNA-34a enhances myocardial ischemia-reperfusion injury via the mitochondrial apoptotic pathway. Free Radical Research. 2022;56(3-4):229-244. https://doi.org/10.1080/10715762.2021.1953004
Li W, Jin S, Hao J, Shi Y, Li W, Jiang L. Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1. Canadian Journal of Physiology and Pharmacology. 2021;99(9):875-884. https://doi.org/10.1139/cjpp-2020-0180
Sun Y, Ren J, Wu W. Effect of MiR-34a on hypertension-induced hypertrophic cardiomyopathy in rats via the TGF-β1/Smads signaling pathway. Minerva Medica. 2021;112(3):405-406.
Costantino S, Paneni F, Luscher T, Cosentino F. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. European Heart Journal. 2016;37(6):572-576. https://doi.org/10.1093/eurheartj/ehv599
Gao L, Wang X, Guo S, Lili Xiao, Liang C, Wang Z, Li Y, Liu Y, Yao R, Liu Y, Zhang Y. LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy. Journal of Cellular Physiology. 2019;234(4):4944-4958. https://doi.org/10.1002/jcp.27296
Ni T, Lin N, Lu W, Sun Z, Lin H, Chi J, Guo H. Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy. Cardiovascular Drugs and Therapy. 2020;34(3):291-301. https://doi.org/10.1007/s10557-020-06968-0
Bernardo BC, Yildiz GS, Kiriazis H, Harmawan CA, Tai CMK, Ritchie RH, McMullen JR. In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function. Cells. 2022;11(19):3117. https://doi.org/10.3390/cells11193117
Wiedmann F, Kraft M, Kallenberger S, Buscher A, Paasche A, Blochberger PL, Seeger T, Javorszky N, Warnecke G, Arif R, Kremer J, Karck M, Frey N, Schmidt C. MicroRNAs Regulate TASK-1 and Are Linked to Myocardial Dilatation in Atrial Fibrillation. Journal of the American Heart Association. 2022;11(7):e023472. https://doi.org/10.1161/JAHA.121.023472
Zhu Y, Feng Z, Cheng W, Xiao Y. MicroRNA-34a mediates atrial fibrillation through regulation of Ankyrin-B expression. Molecular Medicine Reports. 2018;17(6):8457-8465. https://doi.org/10.3892/mmr.2018.8873
Xiao S, Zhou Y, Liu A, Wu Q, Hu Y, Liu J, Zhu H, Yin T, Pan D. Uncovering potential novel biomarkers and immune infiltration characteristics in persistent atrial fibrillation using integrated bioinformatics analysis. Mathematical Biosciences and Engineering. 2021;18(4):4696-4712. https://doi.org/10.3934/mbe.2021238